Carmignac Gestion Invests $469,000 in Pfizer Inc. $PFE

Carmignac Gestion acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 2nd quarter, Holdings Channel reports. The firm acquired 19,475 shares of the biopharmaceutical company’s stock, valued at approximately $469,000.

A number of other large investors have also recently made changes to their positions in PFE. Handelsbanken Fonder AB lifted its stake in shares of Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock worth $59,295,000 after acquiring an additional 232,528 shares during the last quarter. Russell Investments Group Ltd. increased its stake in Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after purchasing an additional 745,213 shares during the period. Leuthold Group LLC bought a new stake in shares of Pfizer during the second quarter worth $4,887,000. North Dakota State Investment Board bought a new stake in shares of Pfizer during the fourth quarter worth $5,348,000. Finally, Park National Corp OH boosted its stake in shares of Pfizer by 332.1% during the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after purchasing an additional 186,053 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s recent rebound was supported by a quarterly earnings report that exceeded analyst expectations on both earnings and revenue, helping restore confidence in the beaten-down pharmaceutical stock. Why Pfizer Stock Was so Healthy in August
• Positive Sentiment: Commentary remains constructive on Pfizer’s approximately 6% dividend yield and the possibility that a strengthening drug pipeline could provide upside beyond income. One analyst cited a $32.72 12-month price target, implying potential appreciation from recent levels. Forget the Dividend: This Could Be the Real Reason to Buy Pfizer Stock Now
• Positive Sentiment: Novartis India agreed to acquire Pfizer brands for $132 million, including an established hypertension treatment. The transaction could provide cash and further streamline Pfizer’s portfolio toward higher-priority products, although its overall financial impact appears limited relative to Pfizer’s size. Novartis India Acquires Pfizer Brands for $132 Million
• Neutral Sentiment: CEO Albert Bourla is scheduled to discuss Pfizer at Morgan Stanley’s Global Healthcare Conference on September 14. Investors may look for updates on the pipeline, strategy, and outlook, but no new operating information was provided in the announcement. Pfizer Invites Public to Listen to Webcast
• Negative Sentiment: Pfizer’s high yield is attracting attention, but investors are being encouraged to choose AbbVie instead because of its stronger dividend-growth profile. This reinforces concerns that Pfizer may offer income today without comparable long-term dividend growth. Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now
• Negative Sentiment: Broader commentary describes Pfizer as still struggling and highlights uncertainty surrounding its post-COVID growth strategy and next-generation drug pipeline. These concerns can limit investor enthusiasm despite the earnings beat and attractive valuation. This Is What I’d Do With Pfizer Stock Right Now

Wall Street Analysts Forecast Growth

Several research firms recently commented on PFE. UBS Group reaffirmed a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Guggenheim dropped their target price on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, JPMorgan Chase & Co. lowered their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer Stock Down 2.4%

Pfizer stock traded down $0.67 during midday trading on Tuesday, hitting $27.78. 31,737,771 shares of the company’s stock were exchanged, compared to its average volume of 41,536,398. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $29.21. The firm has a 50-day moving average of $26.06 and a two-hundred day moving average of $26.34. The company has a market cap of $158.34 billion, a PE ratio of 36.55, a P/E/G ratio of 1.91 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the business posted $0.78 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 24th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. Pfizer’s payout ratio is 226.32%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.